



Subject : Endorsement Letter, BSP Ltd

To whom it may concern:

For the last two and a half years, I have been involved with BSP - Biological Signal Processing Ltd. I supervised the clinical studies that were carried out using BSP's prototype system at the Rabin Medical Center, participated in research and development meetings, and evaluated the clinical potential of the HyperQ technology.

BSP's HyperQ technology is based on sophisticated analysis of the QRS segment of the ECG signal, a part of the signal that is mostly overlooked by currently used clinical methodologies. The QRS segment of the ECG reflects the prominent phase of the heart's activity cycle – the systolic phase, or the contraction. Recent clinical and theoretical studies have indicated that the QRS signal contains crucial information of great diagnostic value that is indicative of ischemic phenomena. Numerous studies have confirmed that cardiac ischemia yields subtle changes in the high-frequency components of the ECG signal, changes that are very difficult to detect due to excessive electrical noise. Among the contributors to these findings were Dr. Amir Beker, BSP's founder, and especially Prof. Shimon Abboud, BSP's scientific consultant.

BSP succeeded in designing and developing the technology for recording and analyzing these ischemic changes, both at rest and during standard clinical exercise test. To the best of my knowledge, BSP's HyperQ system is the only non-invasive solution available today that offers these capabilities.

In clinical tests performed on nearly 100 subjects undergoing standard exercise tests, the HyperQ system demonstrated impressive and very promising results. The diagnostic capabilities achieved were far superior compared to standard ECG-based analysis, and were comparable with the results of the SPECT (nuclear mapping of the heart), a semi-invasive procedure that is much more expensive and complicated.

I believe that the HyperQ system can be easily and quickly adopted by cardiologists, as it is based on non-invasive ECG recording, performed during standard, currently used clinical procedures. In addition, the unique color representation of the results, developed by BSP, is innovative and very accessible to clinicians.

When established, the HyperQ methodology could revolutionize non-invasive cardiology by opening the door to the long sought screening test for ischemic heart disease. In addition, it could serve as an essential tool for monitoring during and after catheterization, in bed-side monitors, in holters and implantable devices.

I was impressed by BSP's excellent team, the development and implementation process and the company's achievements. I strongly endorse BSP and the technology it has developed, and will be happy to assist and take part in helping to promote the market adoption of this technology.

Sincerely,

Prof. Boris Strasberg, MD.

Deputy Director, Cardiology Department, Rabin Medical Center
Director, Arrhythmia and Pacemaker unit, Rabin Medical Center
Professor of Cardiology, Tel Aviv University